We offer a viable solution to the scarcity of fully functional primary human hepatocytes.
Von Baer Wolff is focused on the fabrication of human hepatocytes with one primary goal: To become the premier supplier of iPS-derived human hepatocytes to science and industry.
Our technology is complex but its benefits are easy to measure. Significant cost savings, improved drug safety and effectiveness, and hope for those affected with liver disease. An abundant supply of human hepatocytes empowers researchers to explore new ideas that can positively impact patient outcomes.
We follow three steps to offer this viable solution:
Step 1: Make primary human hepatocytes from stem cells.
Step 2: Modify them using CRISPR/Cas9 gene-editing tools.
Step 3: Mature and multiply them in in vivo incubators.
For the most recent news about vonbaewolff, please visit www.vonbaerwolff.com
Neoolife is a Bio-MedTech start-up company based on tissue-engineering strategies and the University of Pittsburgh – Fondazione RiMED shared IPs developed within the McGowan Institute for Regenerative Medicine.
Neoolife operates as a Delaware C-Corporation and includes an international and multidisciplinary team with sizeable cumulative experience in bio-med technology and device therapy for cardiovascular disease.
Neoolife is focusing on polymeric heart valves and valve tissue.
Neoolife’s revolutionary and unique manufacturing process allows for creating a bioengineered polymeric scaffold (no cell seeding, no animal-derived tissues). Once implanted, this scaffold is progressively replaced by newly generated and growing human heart valve tissue (endogenous in situ tissue regeneration).
Neoolife’s biodegradable polymeric scaffold is made using a novel and unique electrodeposition process called double component deposition (DCD). This technology allows us to:
- Produce polymeric scaffolds that mimic the structure and function of human heart-valve tissue (i.e., aortic, mitral, pulmonary, and tricuspid);
- Produce polymeric scaffolds that promote the intracardiac regeneration of new living tissue, with lifetime durability and resistance to thrombosis and calcification.
Using this innovative technology, Neoolife will:
- Manufacture tailored polymeric scaffolds (patches) to repair the human heart valve and any intracardiac defect;
- Manufacture polymeric heart valve prostheses that are highly compressible and can be loaded into catheters (12-14 French size) and allow for “true” low profile transcatheter technologies;
- Manufacture very low-profile heart-valve prostheses for minimally invasive surgical procedures.
Neoolife’s technology can address the majority of the tissue heart-valves market (surgical and percutaneous). This market will reach globally $ 12.5 billion in revenue by 2025 with a double-digit CAGR. In the specific field of percutaneous treatment of valve disease, Neoolife technology will generate new market opportunities by addressing younger patients and patients with anatomical limitations that are nowadays referred for conventional surgery.
Moreover, the manufacturing of a polymeric patch to repair intracardiac and epicardial defects, including valve pathologies, will further broaden the potential market that Neoolife’s technology could address.
ECM Therapeutics is a regenerative medicine company that develops and manufactures diagnostic and therapeutic products derived from a naturally occurring material called extracellular matrix (ECM).
Cell-based and drug-based approaches for tissue and organ replacement have not met the hopes and expectations of the medical community or the patients in need of such therapies. The reasons are numerous, but the common theme is the failure of cells and engineered tissues to survive following implantation in the patient. An effective strategy to overcome this barrier represents an opportunity to address several serious unmet medical needs and change the practice of medicine.
Naturally occurring biologic materials composed of extracellular matrix (ECM) have been successfully used for almost 20 years as surgical meshes and topical wound products. ECM Therapeutics has developed a hydrogel form of ECM that represents Mother Nature’s version of the ideal “niche” in which cells thrive. The ECM hydrogel promotes a number of constructive wound healing events including: 1) the mobilization and differentiation of the body’s local stem cells, 2) the transformation of the immune system from a pro-inflammatory phenotype to an anti-inflammatory, tissue healing phenotype, and 3) the suppression of abnormal signaling pathways within pre-cancerous and cancer cells. The ECM hydrogel represents a solution to many potential serious medical problems. The first products target esophageal and colorectal disease.
For the most recent news about ECM Therapeutics, please visit www.ecmtherapeutics.com
About AxoMax Technologies, Inc.
AxoMax Technologies, Inc. is a privately-held Pennsylvania C-corp, founded in 2018 by Dr. Kacey Marra. Our core technology is a medical device that is an off-the-shelf nerve guide that can replace the standard of care. The nerve guide, or tube, is called “AxoMax”, for maximum axonal regeneration. We utilize our patented technology to deliver neurotrophic factors in a controlled and long-term fashion from a biodegradable tube. AxoMax® nerve guide has demonstrated the ability to repair traumatic nerve injuries in a pivotal large animal model. Our goal is to revolutionize nerve repair one gap at a time.
Long gap peripheral nerve injuries (i.e., gaps >3cm) remain a clinical challenge. When there is a long gap nerve injury, the standard of care is transplanting a nerve from one place in the body to the area where the defect is, a technique known as autografting. The use of an autograft requires a second surgical site resulting in longer operating times, and typically a sensory nerve is used to replace a motor/sensory nerve, which leaves an area of the body with permanent numbness. There are a handful of nerve guides on the market available to regenerate nerve gaps less than 3cm. However, there are no synthetic guides available having an FDA-approved indication for use in nerve gaps greater than three centimeters. Our patented technology utilizes a biodegradable tube containing a controlled drug delivery system supplying the cues necessary to promote the growth of nerves over large gaps, thus fulfilling this clinical unmet need.
We have developed a biodegradable polymer nerve guide (AxoMax) which locally delivers bioactive neurotropic factors in the proper concentration to cross from the proximal to distal nerve stump. Delivery of a drug that can enhance nerve regeneration is used to overcome the current limitations in nerve repair across large defects.
For the most recent news about AxoMax please visit www.kaceymarra.com
Renerva®, LLC. is a rapidly-growing and innovative medical device company founded in 2017.
Our main focus is to develop and commercialize implantable technologies to improve the outcome of peripheral nerve repair procedures. Renerva’s initial therapeutic focus is on the 500,000 Americans suffering from acute nerve injuries every year, with other indications including the treatment of chronic compressive nerve injuries and other conditions affecting the peripheral nerves.
We are privately held and headquartered in Pittsburgh, Pennsylvania, where we operate in a state-of-the-art laboratory facility.
We are building a stellar team and nourishing a culture of high performance and team cohesiveness with the focused mission of helping patients affected by peripheral nerve injury by advancing nerve recovery and restoring the hope of achieving a good quality of life.
For the most recent news about Renerva®, LLC please visit www.renerva.com